Zevra Therapeutics, Inc. ZVRA Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $95.6M+156% | $62.41M+84.7% | $54.44M+0.7% | $47.71M+21.5% | $37.34M-12.9% | ||
| $105.02M+315% | $128.61M+260% | $145.07M+311% | $154.9M+1,449% | $25.29M+156% | ||
| $22.1M+75.1% | $23.26M+121% | $16.84M+116% | $18.27M+104% | $12.62M+51.9% | ||
| $2.38M-94.1% | $13M-69.3% | $23.12M-43.9% | $31.15M-5.4% | $40.57M+74.2% | ||
| $7K— | —— | —— | —— | —— | ||
| $863K— | —— | —— | —— | —— | ||
| $1.44M— | —— | —— | —— | —— | ||
| $4.94M+31.3% | $7M+72.7% | $7.4M+225% | $4.35M+62.0% | $3.77M+102% | ||
| —— | —— | —— | —— | —— | ||
| $229.97M+182% | $223.01M+159% | $225.12M+126% | $226.34M+272% | $81.57M+29.7% | ||
| $430K+1.9% | $489K+37.4% | $488K-19.6% | $599K-11.7% | $422K-39.3% | ||
| 13.1%-163,599,987% | 13%-65,699,987% | 12.9%-81,999,987% | 12.6%-91,099,987% | 163,600,000%+55,000,000% | ||
| $4.7M0.0% | $4.7M0.0% | $4.7M0.0% | $4.7M— | $4.7M— | ||
| $6.11M-90.9% | $6.42M-90.7% | $6.74M-90.5% | $7.05M— | $67.38M— | ||
| $143K-51.2% | $143K-62.8% | $153K-70.1% | $220K-74.9% | $293K-83.6% | ||
| $82.6M— | —— | —— | —— | —— | ||
| $36.1M— | $47.88M— | $30.9M— | $15.1M— | —— | ||
| $278.58M+61.3% | $284.73M+59.8% | $270.12M+41.0% | $256.28M+77.5% | $172.71M+14.2% | ||
| $11.69M-34.4% | $11.6M-54.4% | $11.07M-54.7% | $15.84M-22.5% | $17.82M-21.8% | ||
| $1.41M-58.6% | $1.36M-39.7% | $8.99M+867% | $6.87M+161% | $3.4M+62.8% | ||
| $406K-31.1% | $419K-0.2% | $441K-18.3% | $525K-11.9% | $589K+1.0% | ||
| $0— | —— | —— | —— | —— | ||
| $20.35M— | $13.71M— | $17.46M— | —— | —— | ||
| $47.03M+74.3% | $39.28M+15.3% | $26.11M-24.3% | $28.83M-5.3% | $26.98M-9.8% | ||
| $0-100% | $61.93M+4.1% | $61.31M+4.1% | $60.69M+4.1% | $60.09M— | ||
| $741K-36.0% | $859K+131% | $966K+100% | $1.06M+94.7% | $1.16M+64.3% | ||
| $1.15M-34.3% | $1.28M+61.4% | $1.41M+37.5% | $1.58M+38.9% | $1.75M+35.6% | ||
| $1.86M-61.9% | $1.71M-63.0% | $4M-27.6% | $3.32M-50.0% | $4.88M-42.9% | ||
| $8.16M-93.8% | $11.12M-92.0% | $136.95M+12.5% | $139.05M+24.2% | $131.69M+28.5% | ||
| $0— | —— | —— | —— | —— | ||
| $6K+20.0% | $6K+20.0% | $6K+20.0% | $6K+50.0% | $5K+25.0% | ||
| $602.75M+7.5% | $588.46M+6.0% | $580.78M+5.5% | $564.32M+17.7% | $560.47M+17.7% | ||
| -$384.17M+24.4% | -$422.06M+16.5% | -$434.23M+7.5% | -$433.68M+0.6% | -$508.39M-22.1% | ||
| -$1.8M-2,091% | -$764K-221% | -$2.42M-2,001% | -$2.43M-677% | -$82K-158% | ||
| $10.98M0.0% | $10.98M0.0% | $10.98M0.0% | $10.98M0.0% | $10.98M0.0% | ||
| $205.8M+402% | $154.66M+290% | $133.17M+90.9% | $117.23M+261% | $41.02M-16.0% | ||
| $278.58M+61.3% | $284.73M+59.8% | $270.12M+41.0% | $256.28M+77.5% | $172.71M+14.2% | ||
| —— | —— | —— | —— | —— | ||
| $0— | —— | —— | —— | —— | ||
| $0— | —— | —— | —— | —— | ||
| $95.6M+156% | $62.41M— | $54.44M— | $47.71M— | $37.34M— | ||
| $105.02M+315% | $128.61M+260% | $145.07M+311% | $154.9M+1,449% | $25.29M+156% | ||
| $143K-51.2% | $143K-62.8% | $153K-70.1% | $220K-74.9% | $293K-83.6% | ||
| —— | —— | —— | —— | —— | ||
| $2M— | —— | —— | —— | —— | ||
| $2M— | —— | —— | —— | —— | ||
| $2M— | —— | —— | —— | —— | ||
| $2M— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $1.09M-33.6% | $1.21M+84.5% | $1.34M+63.0% | $1.5M+64.2% | $1.64M+50.6% | ||
| $36.15M— | $47.88M— | $30.87M— | $15.09M— | —— | ||
| $6.11M-90.9% | $6.42M-90.7% | $6.74M-90.5% | $7.05M— | $67.38M— | ||
| $1.09M-33.6% | $1.21M+84.5% | $1.34M+63.0% | $1.5M+64.2% | $1.64M+50.6% | ||
| $143K-51.2% | $143K-62.8% | $153K-70.1% | $220K-74.9% | $293K-83.6% | ||
| $1.09M-33.6% | $1.21M+84.5% | $1.34M+63.0% | $1.5M+64.2% | $1.64M+50.6% | ||
| $143K-51.2% | $143K-62.8% | $153K-70.1% | $220K-74.9% | $293K-83.6% | ||
| —— | —— | —— | —— | —— | ||
| $11.69M-34.4% | $11.6M-54.4% | $11.07M-54.7% | $15.84M-22.5% | $17.82M-21.8% | ||
| —— | —— | —— | —— | —— | ||
| $13.17M+155% | $12.19M+144% | $5.61M-34.4% | $5.6M-17.3% | $5.17M— | ||
| —— | —— | —— | —— | —— | ||
| $1.41M-58.6% | $1.36M-39.7% | $8.99M+867% | $6.87M+161% | $3.4M+62.8% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $1.15M-98.1% | $63.21M+4.8% | $62.72M+4.7% | $62.28M+4.7% | $61.84M+874% | ||
| —— | —— | —— | —— | —— | ||
| $0.00— | —— | —— | —— | —— | ||
| 60.7M— | —— | —— | —— | —— | ||
| 10M— | —— | —— | —— | —— | ||
| 0— | —— | —— | —— | —— | ||
| 0— | —— | —— | —— | —— | ||
| $602.75M+7.5% | $588.46M+6.0% | $580.78M+5.5% | $564.32M+17.7% | $560.47M+17.7% | ||
| $0— | —— | —— | —— | —— | ||
| $10.98M0.0% | $10.98M0.0% | $10.98M0.0% | $10.98M0.0% | $10.98M0.0% | ||
| $0.00— | —— | —— | —— | —— | ||
| 18.6M— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $6.87M— | $7.03M— | $17.46M— | —— | —— | ||
| $0— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $95.6M+156% | $62.41M— | $54.44M— | $47.71M— | $37.34M— | ||
| —— | —— | —— | —— | —— | ||
| $18.62M— | —— | —— | —— | —— | ||
| $0— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $250M— | —— | —— | —— | —— | ||
| $60.69M— | —— | —— | —— | —— | ||
| $59.11M— | $56.85M— | $56.22M— | —— | —— | ||
| $0— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $6.8M-47.8% | $9.58M-46.2% | $13.77M-1.0% | $15.81M— | $13.03M— | ||
| —— | —— | —— | —— | —— | ||
| $9.48M+1.0% | $9.69M+26.6% | $13.34M+57.1% | $11.86M+46.2% | $9.39M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $2M— | —— | —— | —— | —— | ||
| $7K— | —— | —— | —— | —— | ||
| $82.6M— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $0.13— | —— | —— | —— | —— | ||
| $0— | —— | —— | —— | —— | ||
| $10M— | —— | —— | —— | —— | ||
| $0— | —— | —— | —— | —— | ||
| $0— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Zevra Therapeutics, Inc.'s total assets?
- Zevra Therapeutics, Inc. (ZVRA) holds $278.6M in total assets, up 61.3% year over year.
- How much debt does Zevra Therapeutics, Inc. have?
- Zevra Therapeutics, Inc. carries $1.1M in total debt against $205.8M of shareholders' equity, a debt-to-equity ratio of 0.01.
- How much cash does Zevra Therapeutics, Inc. have?
- Zevra Therapeutics, Inc. holds $95.6M in cash and equivalents.
- Can Zevra Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 4.89 — current assets exceed current liabilities.
- Where does Zevra Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Zevra Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
